<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Toxicities and Duration of Treatment for Immunotherapy in Advanced Metastatic Hepatocellular Carcinoma

minute read

by DocWire News | January 23, 2024
placeholder

CU Cancer Center member Christopher Lieu, MD, and Namrata Vijayvergia, MD, of the Fox Chase Cancer Center conclude their discussion with considerations for managing immunotherapy-related toxicities in patients with metastatic hepatocellular carcinoma (HCC), along with a review of the available evidence regarding the duration of immunotherapy treatment.

Topics: Press Coverage

Comments